You can buy or sell Motif Bio and other stocks, options, ETFs, and crypto commission-free!
Motif Bio plc ADRs, also called Motif Bio, is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Read More It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ.
Princeton, New Jersey
52 Week High
52 Week Low
Seeking AlphaMay 22
Motif Bio to evaluate iclaprim in ophthalmology; shares up 8% premarket
Motif Bio (NASDAQ:MTFB) has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis.